Table 3 Percentage of patients with no draining fistulas at weeks 26 and 56 for all patients with fistulas at baseline (n = 117) stratified by baseline concomitant therapies

Subgroup	No draining fistulas*
Subgroup	Week 26 % of patients	Week 56 % of patients
No baseline immunosuppressant use
Placebo (n = 21)	19	19
Both adalimumab groups (n = 39)	33 (p = 0.369)	36 (p = 0.241)
Baseline immunosuppressant use
Placebo (n = 26)	8	8
Both adalimumab groups (n = 31)	26 (p = 0.092)	29 (p = 0.051)
No baseline CD-related antibiotic use
Placebo (n = 28)	14	14
Both adalimumab groups (n = 44)	32 (p = 0.162)	36 (p = 0.059)
Baseline CD-related antibiotic use
Placebo (n = 19)	11	11
Both adalimumab groups (n = 26)	27 (p = 0.264)	27 (p = 0.264)

*Patients who had no draining fistulas at the last two post-baseline evaluations in the double-blind period on or before the week 26 or week 56 visits were classified as no; otherwise, patients were classified as yes. p Values from χ² tests comparing both adalimumab groups combined versus placebo. CD, Crohn’s disease.